EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation

Sahar Samimi, Taha Hatab, Chloe Kharsa, Safi U Khan, Rody G Bou Chaaya, Fatima Qamar, Joe Aoun, Syed Zaid, Nadeen Faza, Marvin D Atkins, Stephen H Little, William A Zoghbi und 3 weitere

JACC: Cardiovascular Interventions · 2025-01 · 18 (1) · 44-57

DOI: 10.1016/j.jcin.2024.08.042 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JACC: Cardiovascular Interventions, 2025-01. Verfasst von Sahar Samimi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Aortic Valve, Aortic Valve Insufficiency, Heart Valve Prosthesis, Off-Label Use. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter aortic valve replacement (TAVR) for high surgical risk patients with severe native aortic regurgitation (AR) presents unique challenges. Dedicated devices such as the JenaValve (JenaValve Technology) and J-Valve (JC Medical Inc) show promising results in addressing these challenges. OBJECTIVES: This study compares the safety and efficacy of dedicated vs off-label devices among high surgical risk patients with pure native AR. METHODS: We systematically searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials through July 11, 2024, for studies on TAVR among patients with pure severe native AR. The primary endpoint was 30-day all-cause mortality. Secondary endpoints were device success, residual AR ≥ moderate, valve embolization/migration, pacemaker implantation, reintervention, and all-cause mortality at 1 year. Summary estimates were constructed using a random effects model. RESULTS: A total of 34 studies encompassing 2,162 patients (mean age 75.4 ± 0.2 years, 42.8% women) were included in the meta-analysis. Patients undergoing TAVR with dedicated devices had a lower all-cause 30-day mortality rate (3% vs 9%; P < 0.01) and higher device success (93% vs 82%; P < 0.01) compared with off-label devices. The risk of AR ≥ moderate (2% vs 5%; P = 0.03), valve embolization/migration (2% vs 8%; P < 0.01), pacemaker implantation (11% vs 20%; P < 0.01), and reintervention (4% vs 10%; P < 0.01) at 30 days and all-cause mortality at 1 year (6% vs 24%; P < 0.01) were lower in the dedicated device group. CONCLUSIONS: Dedicated TAVR devices for native AR show superior device success and reduced mortality, residual AR, and reintervention rates compared with off-label devices. These findings support the use of dedicated devices as a safer alternative for high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic ValveAortic Valve InsufficiencyHeart Valve ProsthesisOff-Label UseTranscatheter Aortic Valve ReplacementAgedFemaleHumansMalePostoperative ComplicationsProsthesis DesignRecovery of FunctionRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment Outcome

Stichwörter der Autor:innen

dedicated devicepure native aortic regurgitationtranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
  • Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, Texas, USA.
  • Section of Cardiology, Baylor College of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
  • Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: ssgoel@houstonmethodist.org.

Zitieren

APA

Samimi, S., Hatab, T., Kharsa, C., Khan, S. U., Bou Chaaya, R. G., Qamar, F., Aoun, J., Zaid, S., Faza, N., Atkins, M. D., Little, S. H., Zoghbi, W. A., Reardon, M. J., Kleiman, N. S., & Goel, S. S. (2025). Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation. JACC: Cardiovascular Interventions, 18(1), 44-57. https://doi.org/10.1016/j.jcin.2024.08.042

Vancouver

Samimi S, Hatab T, Kharsa C, Khan SU, Bou Chaaya RG, Qamar F, et al. Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation. JACC: Cardiovascular Interventions. 2025;18(1):44-57. doi:10.1016/j.jcin.2024.08.042

BibTeX
@article{Samimi2025,
  author = {Samimi, Sahar and Hatab, Taha and Kharsa, Chloe and Khan, Safi U and Bou Chaaya, Rody G and Qamar, Fatima and Aoun, Joe and Zaid, Syed and Faza, Nadeen and Atkins, Marvin D and Little, Stephen H and Zoghbi, William A and Reardon, Michael J and Kleiman, Neal S and Goel, Sachin S},
  title = {Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {44--57},
  doi = {10.1016/j.jcin.2024.08.042}
}
Kostenlos starten →